Core Viewpoint - Ardelyx (ARDX) has received a new patent for its oral formulations of tenapanor, which is significant for its commercial products Isbrela and Xphozah, with the patent set to expire on November 26, 2042 [1] Group 1 - The United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,539,299 titled "Oral Formulations of Tenapanor" [1] - The patent covers the commercial formulations of Isbrela and Xphozah [1] - The patent will be submitted to the Food and Drug Administration (FDA) for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations for both products [1]